EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis

Jenny-Hoa Nguyen, Mirna Chehade iD, Evan S Dellon iD, Allen Radin iD, Jason Chittenden, Mohamed A Kamal, Margee Louisias, Christine Xu, Matthew P Kosloski iD

Clinical Pharmacology & Therapeutics · 2026-06 · 119 (6) · 1555-1564

DOI: 10.1002/cpt.70233 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 26.02.2026. Verfasst von Jenny-Hoa Nguyen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Antibodies, Monoclonal, Humanized, Models, Biological. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dupilumab, a fully human monoclonal antibody that blocks key drivers of type 2 inflammation, is approved across 8 diseases, including eosinophilic esophagitis. Subcutaneous dupilumab 300 mg weekly improved outcomes vs. placebo in adults (aged ≥ 18 years) and adolescents (aged ≥ 12 to < 18 years) during the phase III LIBERTY EoE TREET study (NCT03633617). The phase III EoE KIDS study (NCT04394351) demonstrated efficacy of a weight‐tiered, higher exposure dupilumab dose approximating 300 mg weekly exposure in TREET vs. placebo in children aged ≥ 1 to < 12 years. To characterize dupilumab pharmacokinetics, inform clinical trial design, and optimize posology, a population pharmacokinetic model was developed using dupilumab concentration data from 6 single‐dose studies in healthy adults and 3 eosinophilic esophagitis clinical trials. Healthy volunteer data were used to construct a stable base model; incorporation of patient data allowed estimation covariate effects for the disease population. Observational data from up to 52 weeks of treatment in eosinophilic esophagitis trials validated model performance. Significant effects were identified for body weight on clearance and volume of distribution, including time‐varying weight in children and adolescents, and of albumin on clearance; age was not a significant covariate. Simulations identified alternative dupilumab regimens for patients weighing ≥ 5 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisAntibodies, Monoclonal, HumanizedModels, BiologicalHumansAdolescentChildFemaleMaleAdultChild, PreschoolYoung AdultAge FactorsBody WeightInjections, Subcutaneous

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
  • Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Sanofi, Cambridge, Massachusetts, USA.
  • Sanofi, Morristown, New Jersey, USA.

ORCID-Profile: Mirna Chehade, Evan S Dellon, Allen Radin, Matthew P Kosloski

Zitieren

APA

Nguyen, J. H., Chehade, M., Dellon, E. S., Radin, A., Chittenden, J., Kamal, M. A., Louisias, M., Xu, C., & Kosloski, M. P. (2026). Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis. Clinical Pharmacology & Therapeutics, 119(6), 1555-1564. https://doi.org/10.1002/cpt.70233

Vancouver

Nguyen JH, Chehade M, Dellon ES, Radin A, Chittenden J, Kamal MA, et al. Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis. Clinical Pharmacology & Therapeutics. 2026;119(6):1555-1564. doi:10.1002/cpt.70233

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Jenny-Hoa and Chehade, Mirna and Dellon, Evan S and Radin, Allen and Chittenden, Jason and Kamal, Mohamed A and Louisias, Margee and Xu, Christine and Kosloski, Matthew P},
  title = {Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {119},
  number = {6},
  pages = {1555--1564},
  doi = {10.1002/cpt.70233}
}
Kostenlos starten →